The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review


Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' conclusions
Report found that it is not currently possible to recommend pharmacogenetic testing for CYP2D6 in women with oestrogen receptor-positive breast cancer who are receiving treatment with tamoxifen.

Project page URL
http://www.hta.ac.uk/2167

URL for DARE abstract
http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?AccessionNumber=12011007535& UserID=0

Indexing Status
Subject indexing assigned by CRD

MeSH
Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Genotypes; Biomarkers, Tumor

Language Published
English

Country of organisation
England

Address for correspondence
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk

AccessionNumber
32010000281

Date abstract record published
14/04/2010